Supergoop!® announces its partnership with entrepreneur and international tennis sensation Maria Sharapova, welcoming her to the Supergoop! team as a co-owner with Founder and CEO Holly Thaggard. Supergoop! is the first and only multi-functional skincare line in prestige distribution with a foundation in UV protection and 100% dedication to sun safety. This partnership will be a vehicle for Supergoop! to spotlight the brand’s mission to elevate skin cancer awareness alongside the many skincare and beauty benefits attributed to applying UV protection every single day.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7190451-supergoop-partnership-tennis-maria-sharapova-sun-protection-skincare
Calling All Astronauts release their sixth single of the Covid 19 pandemic. "Resist" (Single Version) on February 19th. Mixed by double Grammy winner Alan Branch (Nine Inch Nails, U2, Depeche Mode), Trump may have gone but the war on fascism is far from over, Resist charts the resurgence of ANTIFA as a broad spectrum of people say "enough is enough" and stand together against the rise of populism and far right politics determined that another Kristallnacht (Night of broken glass) can't be allowed to happen.
In true DIY ethics not only did the guys recorded the track themselves, they have also once again made the accompanying video, this time remaking War Of The Worlds in just 3 minutes please check it out
Spotify - Deezer - Apple Music
New Single is Now Available on iTunes! Buy R&B and Pop track "Fight For This" by Aden Ray. Click: https://itunes.apple.com/us/artist/aden-ray/id639987516
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The new SnowShredder™ serrated auger on single-stage snowblowers built by the Briggs & Stratton Power Products Group lets you easily clear snow and ice, including that tough and compacted end-of-the-driveway snow left behind by the snowplow. When matched with the Briggs & Stratton 1150 Snow Series™ engine, you can clear snow more than 30% faster compared to the Company’s other single stage snowthrowers.1
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7317651-snowshredder-serrated-auger-simplicity-snapper-briggs-and-stratton-snowblowers/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
